drugset / Trial / NCT03961334
MidregiOnal Proatrial Natriuretic Peptide to Guide SEcondary Stroke Prevention
RandomizedParallel-groupOpen-labelPrevention
Summary
The present trial is addressing the question if a biologically distinct subgroup of ischemic stroke patients without known atrial fibrillation at admission, selected by a cut-off level of MRproANP concentration, which represents a underlying increased risk of cardiac thrombogenicity, benefits from direct oral anticoagulation (DOAC) within 7 days of symptom onset versus standard of care (antiplatelet) as preventive treatment.
Timeline
- Start
- 2019-12-05
- Primary completion
- 2025-01-31
- Completion
- 2026-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Apixaban | Small molecule | 5 mg | — |
| Comparator | Aspirin | Small molecule | 100 mg | — |
| Comparator | Clopidogrel | Small molecule | 75 mg | — |
| Subject | Dabigatran | Unknown | 150 mg | — |
| Subject | Edoxaban | Small molecule | 60 mg | — |